

# Development of ASO therapeutics to treat childhood intractable epilepsy



NEUROSCIENCE	Candidate
Product Type	Antisense oligonucleotide (ASO)
Indication	Childhood intractable epilepsy
Target	Undisclosed
MoA(Mechanism of Action)	RNase H1-mediated target mRNA degradation by distinct ASO-RNA hybridization
Competitiveness	ASO, as RNA therapeutics, works at the RNA level, not the protein level, and has a distinct mode of action by DNA-RNA complementary hybridization, recently attracting worldwide attention as a treatment for intractable neurological disorders.
Development Stage	Candidate
Route of Administration	Intrathecal injection